Experienced in Childhood Acute Myeloid Leukemia

Dr. Lindsay C. Overton

Hematology Oncology | Hematology | Oncology
Central Washington Health Services Association
1201 S Miller St, 
Wenatchee, WA 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Experienced in Childhood Acute Myeloid Leukemia
Central Washington Health Services Association
1201 S Miller St, 
Wenatchee, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Lindsay Overton is a Hematologist Oncology specialist and a Hematologist in Wenatchee, Washington. Dr. Overton has been practicing medicine for over 17 years and is rated as an Experienced provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Primary Lymphoma of the Brain, Paget Disease of the Breast, Myelodysplastic Syndrome (MDS), and Large-Cell Immunoblastic Lymphoma. Dr. Overton is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
New York Medical College, 2008
Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
Confluence Health Hospital
Lake Chelan Community Hospital
Kittitas Valley Community Hospital
Languages Spoken
English
French
Hindi
Punjabi
Telugu
Vietnamese
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PacificSource
  • PPO
Premera
  • EPO
  • PPO

Locations

CENTRAL WASHINGTON HEALTH SERVICES ASSOCIATION
1201 S Miller St, Wenatchee, WA 98801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Latinos' Beliefs and Communication About Advance Care Planning
Latinos' Beliefs and Communication About Advance Care Planning
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: Zimberelimab, Domvanalimab, Etrumadenant
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Enrollment Status: Completed
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 2
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: EndoTAG-1, Gemcitabine
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: September 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction
Enrollment Status: Completed
Publish Date: June 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 16, 2021
Intervention Type: Drug, Other
Study Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Study Phase: Phase 2
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
Enrollment Status: Terminated
Publish Date: February 03, 2021
Intervention Type: Other
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Enrollment Status: Completed
Publish Date: July 23, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 15 Less Clinical Trials

2 Total Publications

Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design.
Journal: Future oncology (London, England)
Published: November 01, 2018
Similar Doctors
Advanced in Childhood Acute Myeloid Leukemia
Dr. Julie G. Smith
Hematology Oncology | Hematology | Oncology
Advanced in Childhood Acute Myeloid Leukemia
Dr. Julie G. Smith
Hematology Oncology | Hematology | Oncology

Central Washington Health Services Association

1201 S Miller St, 
Wenatchee, WA 
 (0.1 mi)
509-662-2208
Languages Spoken:
English, Filipino, Italian, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Julie Smith is a Hematologist Oncology specialist and a Hematologist in Wenatchee, Washington. Dr. Smith and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Waldenstrom Macroglobulinemia, Paget Disease of the Breast, Breast Cancer, and Familial Colorectal Cancer. Dr. Smith is currently accepting new patients.

Advanced in Childhood Acute Myeloid Leukemia
Dr. Mitchell A. Garrison
Hematology Oncology | Hematology | Oncology
Advanced in Childhood Acute Myeloid Leukemia
Dr. Mitchell A. Garrison
Hematology Oncology | Hematology | Oncology

Central Washington Health Services Association

1201 S Miller St, 
Wenatchee, WA 
 (0.1 mi)
509-662-2208
Languages Spoken:
English, French, Mandarin, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mitchell Garrison is a Hematologist Oncology specialist and a Hematologist in Wenatchee, Washington. Dr. Garrison and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, and Primary Lymphoma of the Brain. Dr. Garrison is currently accepting new patients.

Advanced in Childhood Acute Myeloid Leukemia
Dr. Mario Chenal
Hematology Oncology | Hematology | Oncology
Advanced in Childhood Acute Myeloid Leukemia
Dr. Mario Chenal
Hematology Oncology | Hematology | Oncology

Yakima Valley Memorial Physicians

2811 Tieton Dr, 
Yakima, WA 
 (57.2 mi)
509-575-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mario Chenal is a Hematologist Oncology specialist and a Hematologist in Yakima, Washington. Dr. Chenal and is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Colorectal Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Overton's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 75 Advanced Conditions
    View All 176 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile